Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC22A12 | Q96S37 | 20/20 | 0.74 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.74 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.74 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.74 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.74 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.74 |
| ▸ | SLC22A11 | Q9NSA0 | 1/20 | 0.74 |
| ▸ | SLC2A9 | Q9NRM0 | 3/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL249022 | 0.89 | SLC22A12 (0.78) | SLC22A12CYP2C9CYP2C19CYP1A2CYP3A4 | |
| SCHEMBL19987624 | 0.88 | SLC22A12 (0.79) | SLC22A12CYP2C9CYP2C19CYP1A2CYP3A4 | |
| SCHEMBL4736112 | 0.88 | SLC22A12 (0.75) | SLC22A12CYP2C9CYP2C19CYP1A2CYP3A4 | |
| SCHEMBL13445169 | 0.87 | SLC22A12 (0.78) | SLC22A12CYP2C9CYP2C19CYP1A2CYP3A4 | |
| SCHEMBL4735350 | 0.86 | SLC22A12 (0.82) | SLC22A12CYP2C9CYP2C19CYP1A2CYP3A4 | |
| SCHEMBL16310802 | 0.86 | SLC22A12 (0.78) | SLC22A12CYP2C9CYP2C19CYP1A2CYP3A4 | |
| SCHEMBL11915751 | 0.85 | SLC22A12 (0.71) | SLC22A12CYP2C9CYP2C19CYP1A2CYP3A4 | |
| Lesinurad SCHEMBL842962 | 0.85 | SLC22A12 (1.00) | SLC22A12CYP2C9CYP2C19CYP1A2CYP3A4 | |
| Lesinurad SCHEMBL29353441 | 0.85 | SLC22A12 (1.00) | SLC22A12CYP2C9CYP2C19CYP1A2CYP3A4 | |
| SCHEMBL4735395 | 0.84 | SLC22A12 (0.70) | SLC22A12CYP2C9CYP2C19CYP1A2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190142805-A1 | Novel Compounds and Compositions and Methods of Use | ARDEA BIOSCIENCES INC. | 2019-05-16 | — | — | US | disclosed |
| US-10183012-B2 | Compounds and compositions and methods of use | ARDEA BIOSCIENCES, INC. (US) | 2019-01-22 | — | — | US | disclosed |
| US-20170281601-A1 | NOVEL COMPOUNDS AND COMPOSITIONS AND METHODS OF USE | ARDEA BIOSCIENCES, INC. | 2017-10-05 | — | — | US | disclosed |
| US-20170281601-A1 | NOVEL COMPOUNDS AND COMPOSITIONS AND METHODS OF USE | ARDEA BIOSCIENCES, INC. | 2017-10-05 | — | — | US | disclosed |
| US-20160221970-A1 | NOVEL COMPOUNDS AND COMPOSITIONS AND METHODS OF USE | ARDEA BIOSCIENCES, INC. | 2016-08-04 | — | — | US | disclosed |
| US-20160221970-A1 | NOVEL COMPOUNDS AND COMPOSITIONS AND METHODS OF USE | ARDEA BIOSCIENCES, INC. | 2016-08-04 | — | — | US | disclosed |
| US-20160221969-A1 | Compounds, compositions and methods of using same for modulating uric acid levels | ARDEA BIOSCIENCES, INC. | 2016-08-04 | — | — | US | disclosed |
| US-20160221969-A1 | Compounds, compositions and methods of using same for modulating uric acid levels | ARDEA BIOSCIENCES, INC. | 2016-08-04 | — | — | US | disclosed |
| US-20140128338-A1 | COMPOUNDS, COMPOSITIONS AND METHODS OF USING SAME FOR MODULATING URIC ACID LEVELS | ARDEA BIOSCIENCES, INC. (US) | 2014-05-08 | — | — | US | disclosed |
| US-20140128338-A1 | COMPOUNDS, COMPOSITIONS AND METHODS OF USING SAME FOR MODULATING URIC ACID LEVELS | ARDEA BIOSCIENCES, INC. (US) | 2014-05-08 | — | — | US | disclosed |
| US-20110293719-A1 | NOVEL COMPOUNDS AND COMPOSITIONS AND METHODS OF USE | ARDEA BIOSCIENCES, INC. (US) | 2011-12-01 | — | — | US | disclosed |
| US-20110293719-A1 | NOVEL COMPOUNDS AND COMPOSITIONS AND METHODS OF USE | ARDEA BIOSCIENCES, INC. (US) | 2011-12-01 | — | — | US | disclosed |
| US-20110268801-A1 | NOVEL COMPOUNDS AND COMPOSITIONS AND METHODS OF USE | ARDEA BIOSCIENCES, INC. (US) | 2011-11-03 | — | — | US | disclosed |
| US-20110268801-A1 | NOVEL COMPOUNDS AND COMPOSITIONS AND METHODS OF USE | ARDEA BIOSCIENCES, INC. (US) | 2011-11-03 | — | — | US | disclosed |
| US-20100056464-A1 | COMPOUNDS, COMPOSITIONS AND METHODS OF USING SAME FOR MODULATING URIC ACID LEVELS | ARDEA BIOSCIENCES (US) | 2010-03-04 | — | — | US | disclosed |
| US-20100056464-A1 | COMPOUNDS, COMPOSITIONS AND METHODS OF USING SAME FOR MODULATING URIC ACID LEVELS | ARDEA BIOSCIENCES (US) | 2010-03-04 | — | — | US | disclosed |
| US-20100056465-A1 | COMPOUNDS, COMPOSITIONS AND METHODS OF USING SAME FOR MODULATING URIC ACID LEVELS | ARDEA BIOSCIENCES (US) | 2010-03-04 | — | — | US | disclosed |
| US-20100056465-A1 | COMPOUNDS, COMPOSITIONS AND METHODS OF USING SAME FOR MODULATING URIC ACID LEVELS | ARDEA BIOSCIENCES (US) | 2010-03-04 | — | — | US | disclosed |
| US-20090197825-A1 | NOVEL COMPOUNDS AND COMPOSITIONS AND METHODS OF USE | ARDEA BIOSCIENCES, INC. (US) | 2009-08-06 | — | — | US | disclosed |
| US-20090197825-A1 | NOVEL COMPOUNDS AND COMPOSITIONS AND METHODS OF USE | ARDEA BIOSCIENCES, INC. (US) | 2009-08-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100056465-A1 | COMPOUNDS, COMPOSITIONS AND METHODS OF USING SAME FOR MODULATING URIC ACID LEVELS | XDH, PON1, OAT | SLC22A12 1095/4885CYP2C9 1309/4885CYP2C19 1898/4885 |
| US-20140128338-A1 | COMPOUNDS, COMPOSITIONS AND METHODS OF USING SAME FOR MODULATING URIC ACID LEVELS | XDH, PON1, OAT | SLC22A12 1095/4885CYP2C9 1309/4885CYP2C19 1898/4885 |
| US-20090197825-A1 | NOVEL COMPOUNDS AND COMPOSITIONS AND METHODS OF USE | XDH, PON1, GLS | SLC22A12 1122/4885CYP2C9 1526/4885CYP2C19 1696/4885 |
| US-20160221969-A1 | Compounds, compositions and methods of using same for modulating uric acid levels | XDH, PON1, OAT | SLC22A12 1095/4885CYP2C9 1309/4885CYP2C19 1898/4885 |
| US-10183012-B2 | Compounds and compositions and methods of use | XDH, PON1, OAT | SLC22A12 815/4885CYP2C9 762/4885CYP2C19 905/4885 |
| US-20110268801-A1 | NOVEL COMPOUNDS AND COMPOSITIONS AND METHODS OF USE | XDH, PON1, GLS | SLC22A12 1122/4885CYP2C9 1526/4885CYP2C19 1696/4885 |
| US-20100056464-A1 | COMPOUNDS, COMPOSITIONS AND METHODS OF USING SAME FOR MODULATING URIC ACID LEVELS | XDH, PON1, OAT | SLC22A12 1095/4885CYP2C9 1309/4885CYP2C19 1898/4885 |
| US-20160221970-A1 | NOVEL COMPOUNDS AND COMPOSITIONS AND METHODS OF USE | XDH, PON1, GLS | SLC22A12 1122/4885CYP2C9 1526/4885CYP2C19 1696/4885 |
| US-20170281601-A1 | NOVEL COMPOUNDS AND COMPOSITIONS AND METHODS OF USE | XDH, PON1, GLS | SLC22A12 1122/4885CYP2C9 1526/4885CYP2C19 1696/4885 |
| US-20110293719-A1 | NOVEL COMPOUNDS AND COMPOSITIONS AND METHODS OF USE | XDH, PON1, GLS | SLC22A12 1122/4885CYP2C9 1526/4885CYP2C19 1696/4885 |
| US-20190142805-A1 | Novel Compounds and Compositions and Methods of Use | XDH, PON1, GLS | SLC22A12 1122/4885CYP2C9 1526/4885CYP2C19 1696/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.